Tag Archives: arterial hypertension

Correlation Study of Serum Zinc Concentration and Retina Layer Thickness in Hypertensive Patients

DOI: 10.2478/amma-2020-0017

Objective: The aim of our study was to evaluate whether blood serum zinc concentration correlates with the thickness of human retina layers, in hypertensive patients with microvascular damage.
Methods: Retinas of elderly patients with arterial hypertension and microvascular damage were imaged using a swept-source ocular coherence tomography from Topcon. Automatic retinal segmentation was applied on a 6mm X 6mm scan protocol and average thickness for 5 examined layers was used for statistical analysis. Serum zinc concentration was measured using the Zinc Assay kit from Sentinel Diagnostics in a spectrophotometric method.
Results: The average age of the twenty-three enrolled patients was 70 years, varying between 62 and 76. The mean zinc value was 9.9 µmol/l ±1.62 (SD). All five examined layers of the retina presented inverse correlation with serum zinc concentration. The complex including the inner plexiform layer and ganglion cell layer indicated the Spearman’s (rho) correlation coefficient -0.42 and a significance level of p=0.04. Patients in high-Zn group (≥ 9.87 µmol/l) had thinner macular retina layers, most importantly in the inner-plexiform layer-ganglion cell layer complex (p=0.006).
Conclusions: Our study has found that serum zinc concentration is inversely correlated with the thickness of retina layers with statistical relevancy in the inner plexiform layer – ganglion cell layer complex. This finding emerges experimental studies in order to elucidate its clinical significance and to evaluate whether the fine architecture of the inner retina has the potential to benefit from oral zinc supplementation through modulating serum levels of zinc in patients with microvascular-damaging diseases.

Full text: PDF

Pulmonary Arterial Hypertension: A New Challenge

Pulmonary hypertension represents a new challenge for the current clinical practice, as recent advances in the field of diagnostic technologies led a to significant increase in the number of patients diagnosed with this disease and in the same time new therapeutic classes proved to have a significant role in improving survival of these patients.
The main types of pulmonary hypertension are the idiopathic form, called primary pulmonary arterial hypertension (PAH) and the secondary one, developed in the evolution of a cardiac disease, in many cases consequence of a congenital heart disease. Once occurred, PAH severely limits the life expectancy. Despite the recent introduction of many new therapeutic agents which are expected to have a revolutionary role in the improvement of life expectancy and quality of life of these patients, PAH continues to be associated with a mortality as high as 35% at 3 years after the diagnosis. The new therapies are mainly represented by vasodilators that target the nitric oxide, endothelin and prostacyclin pathways.
The diagnosis of PAH is usually established when a typical pattern of pre-capillary pulmonary hypertension is encountered in the hemodynamic profile, in the absence of any lung disease. [More]

Full text: PDF